Guided Therapeutics (GTHP) 0.1051 $GTHP
Guided Therapeutics Announces $4 Million Private Placement
Business Wire - Tue Jun 30, 7:30AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that it has entered into a securities purchase agreement with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross cash proceeds to the Company are expected to be approximately $4.0 million, prior to the payment of placement agent fees and expenses.
2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations
M2 - Mon Jun 29, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phj84s/2015_market) has announced the addition of the "2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" report to their offering. 2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations is a new study of the major business opportunities emerging in the US cancer diagnostics market during the nextfive years. The report examines trends in the US market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the US cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. US Market Overview - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments in the US. Business Opportunities and Strategic Recommendations - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test - Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines Supplier Shares, Sales and Volume Forecasts - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories - Physician Offices/Group Practices - Cancer Clinics - Ambulatory Care Centers Instrumentation Review - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment - Assessment of latest technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies - Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/ph...015_market
MYGN: 34.32 (+0.82), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
M2 - Thu Jun 18, 12:14PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x472n5/2015_cancer) has announced the addition of the "2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA - The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/x4...015_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape
M2 - Wed Jun 10, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2gxv/2015_new) has announced the addition of the "2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape (Datapack)" database table to their offering. This is a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Worldwide Market Overview: - Five-year test volume and sales projections by country. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country. - Estimated universe of laboratories performing cancer diagnostic testing by country. - Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Companies Mentioned - Abbott - AdnaGen - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/8s2gxv/2015_new
ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Wed Jun 10, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njc9tc/2015_new) has announced the addition of the "2015 New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)" database table to their offering. This is a new study of the major business opportunities emerging in the German cancer diagnostics market during the next five years. The report examines trends in the German cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. German Market Overview: - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/njc9tc/2015_new
MYGN: 34.32 (+0.82), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)
M2 - Wed Jun 10, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5ptkf/2015_new) has announced the addition of the "2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)" report to their offering. This is a new study of the major business opportunities emerging in the Italian cancer diagnostics market during the next five years. The report examines trends in the Italian cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Italian Market Overview: - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Supplier Shares, Sales and Volume Forecasts: - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories Instrumentation Review: - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment: - Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies: - Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Bckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/t5ptkf/2015_new
SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
Turkish Ministry of Health Expanding Usage of Guided Therapeutics' LuViva(R) Advanced Cervical Scan Driving Significant New Orders
Business Wire - Wed Jun 10, 8:26AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its Turkish distribution partner, ITEM Medical Technologies, has received a significant new order from the National Ministry of Health as it expands usage of the LuViva(R) Advanced Cervical Scan for screening in 2015. The new order of 100 LuViva devices and 100,000 single-use Cervical Guides supplements previous orders, and is also based in part on the Ministry of Health's acceptance of LuViva in government training centers and university hospitals. The orders are expected to be filled starting in October.
Guided Therapeutics Awarded Multiple Tenders for LuViva(R) Advanced Cervical Scan Systems from Governments in Bangladesh
Business Wire - Thu Jun 04, 7:30AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its distributor in Bangladesh has been awarded contracts for four additional LuViva(R) Advanced Cervical Scan systems for use in the country's cervical cancer screening program. The latest awards double the number of LuViva units purchased by various government agencies in Bangladesh to eight.
2015 Strategies in the Global Tumor Marker Testing Market
M2 - Fri May 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kj6pzz/2015_strategies) has announced the addition of the "2015 Strategies in the Global Tumor Marker Testing Market: US, Europe, Japan" report to their offering. Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five yearsExamines trends in the U.S., Europe and JapanReviews current and emerging tumor markersAnalyzes applications of emerging diagnostic technologiesForecasts sales of major tumor markers by country and market segmentProfiles leading market players and potential entrants Companies Mentioned: - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Enzo Biochem - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher/Life Technologies - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/kj...strategies
MYGN: 34.32 (+0.82), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
Guided Therapeutics strikes out again with LuViva PMA
Seeking Alpha - at Seeking Alpha - Tue May 19, 5:10PM CDT
FDA Completes Review of Guided Therapeutics' LuViva(R) Advanced Cervical Scan PMA Application
Business Wire - Tue May 19, 3:05PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval (PMA) application for the LuViva(R) Advanced Cervical Scan. In its most recent communication, FDA advised the Company that its PMA amendment, filed in July 2014, was not approvable in its current form. While the agency advised the Company that more patient data would likely be necessary to amend the current application, the agency also stated its willingness to consider alternative approaches to move the product to approvable form.
Guided Therapeutics' (GTHP) CEO Gene Cartwright on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 1:54PM CDT
Guided Therapeutics Reports First Quarter 2015 Results
Business Wire - Wed May 13, 3:05PM CDT
--FDA response on amended LuViva PMA application expected by end of May
County Government of Nairobi, Kenya Purchases Initial LuViva(R) Advanced Cervical Scan for Cervical Cancer Screening Program
Business Wire - Wed May 06, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that Stem World Enterprises, its distributor for East Africa, has been awarded a contract with the Nairobi County Health Services Sector to supply the first LuViva(R) Advanced Cervical Scan for the agency's cervical cancer screening program.
Guided Therapeutics to Report First Quarter 2015 Results and Hold Conference Call; Provide Update on LuViva FDA Timing
Business Wire - Wed Apr 29, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a point-of-care and painless testing platform that uses biophotonics for the early detection of disease that leads to cervical cancer, today announced that it is scheduled to report financial results for its first quarter ended March 31, 2015 and provide an update on business activity on Wednesday, May 13, 2015, after the market closes.
Penny Stocks Alerts for NEW GENERATION CONSU, Vapor Group, Guided Therapeutics, Jammin Java, MassRoots, and Max Sound
PR Newswire - Tue Apr 21, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: NEW GENERATION CONSU (OTCMKTS:NGCG), Vapor Group (OTCMKTS:VPOR), Guided Therapeutics (OTCBB:GTHP), Jammin Java (OTCMKTS:JAMN), MassRoots (OTCMKTS:MSRT), and Max Sound (OTCBB:MAXD).
Canadian Pilot Programs Initiated with LuViva(R) Advanced Cervical Scan for Provincial-level Cancer Care Support
Business Wire - Tue Apr 21, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today an initiative for procuring provincial-level support for its LuViva Advanced Cervical Scan. The initiative is based on discussions with women's healthcare experts across Canada, whose interest has increased after reviewing positive results from two previous evaluations completed in Halifax, Nova Scotia, with Dr. James Bentley and most recently in London, Ontario, with Drs. Robert DiCecco and Monique Bertrand.
Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
ChinaBio Today - at Seeking Alpha - Sat Apr 18, 12:07PM CDT
Deals and Financings Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an...
BSX: 17.60 (+0.15), ARGS: 6.45 (+0.69), PKI: 51.53 (+0.51)
Guided Therapeutics Completes Interim Financing; Initiating Distribution of LuViva(R) Advanced Cervical Scan in China
Business Wire - Wed Apr 15, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has completed the sale of 4.0 million shares of our common stock and warrants to purchase an additional 2.0 million shares, for an aggregate purchase price of $720,000 in a private placement to accredited investors.
Guided Therapeutics Ships First Commercial LuViva(R) Advanced Cervical Scans to Indonesia
Business Wire - Wed Apr 08, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has shipped two LuViva(R) Advanced Cervical Scans to Indonesia to begin cervical cancer screening evaluations in the world's fourth most populous country.
Guided Therapeutics Announces $4 Million Private Placement
Business Wire - Tue Jun 30, 7:30AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that it has entered into a securities purchase agreement with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross cash proceeds to the Company are expected to be approximately $4.0 million, prior to the payment of placement agent fees and expenses.
2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations
M2 - Mon Jun 29, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phj84s/2015_market) has announced the addition of the "2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" report to their offering. 2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations is a new study of the major business opportunities emerging in the US cancer diagnostics market during the nextfive years. The report examines trends in the US market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the US cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. US Market Overview - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments in the US. Business Opportunities and Strategic Recommendations - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test - Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines Supplier Shares, Sales and Volume Forecasts - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories - Physician Offices/Group Practices - Cancer Clinics - Ambulatory Care Centers Instrumentation Review - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment - Assessment of latest technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies - Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/ph...015_market
MYGN: 34.32 (+0.82), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), CPHD: 58.15 (+0.75), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
M2 - Thu Jun 18, 12:14PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x472n5/2015_cancer) has announced the addition of the "2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA - The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/x4...015_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MYGN: 34.32 (+0.82), A: 39.40 (+0.48), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape
M2 - Wed Jun 10, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2gxv/2015_new) has announced the addition of the "2015 New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape (Datapack)" database table to their offering. This is a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Worldwide Market Overview: - Five-year test volume and sales projections by country. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country. - Estimated universe of laboratories performing cancer diagnostic testing by country. - Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Companies Mentioned - Abbott - AdnaGen - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/8s2gxv/2015_new
ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape
M2 - Wed Jun 10, 9:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njc9tc/2015_new) has announced the addition of the "2015 New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)" database table to their offering. This is a new study of the major business opportunities emerging in the German cancer diagnostics market during the next five years. The report examines trends in the German cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. German Market Overview: - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/njc9tc/2015_new
MYGN: 34.32 (+0.82), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), DHR: 86.65 (+0.91), HOLX: 38.71 (+0.75)
2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)
M2 - Wed Jun 10, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5ptkf/2015_new) has announced the addition of the "2015 New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape (Datapack)" report to their offering. This is a new study of the major business opportunities emerging in the Italian cancer diagnostics market during the next five years. The report examines trends in the Italian cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Italian Market Overview: - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments. Business Opportunities and Strategic Recommendations: - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test: - Biochemical Markers - Oncogenes - Growth Factors - Hormones - Colony Stimulating Factors - Lymphokines - Immunohistochemical Stains, and others. Supplier Shares, Sales and Volume Forecasts: - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories Instrumentation Review: - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment: - Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies: - Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Bckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Polymedco - PreMD - Qiagen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/t5ptkf/2015_new
SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), A: 39.40 (+0.48), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
Turkish Ministry of Health Expanding Usage of Guided Therapeutics' LuViva(R) Advanced Cervical Scan Driving Significant New Orders
Business Wire - Wed Jun 10, 8:26AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its Turkish distribution partner, ITEM Medical Technologies, has received a significant new order from the National Ministry of Health as it expands usage of the LuViva(R) Advanced Cervical Scan for screening in 2015. The new order of 100 LuViva devices and 100,000 single-use Cervical Guides supplements previous orders, and is also based in part on the Ministry of Health's acceptance of LuViva in government training centers and university hospitals. The orders are expected to be filled starting in October.
Guided Therapeutics Awarded Multiple Tenders for LuViva(R) Advanced Cervical Scan Systems from Governments in Bangladesh
Business Wire - Thu Jun 04, 7:30AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its distributor in Bangladesh has been awarded contracts for four additional LuViva(R) Advanced Cervical Scan systems for use in the country's cervical cancer screening program. The latest awards double the number of LuViva units purchased by various government agencies in Bangladesh to eight.
2015 Strategies in the Global Tumor Marker Testing Market
M2 - Fri May 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kj6pzz/2015_strategies) has announced the addition of the "2015 Strategies in the Global Tumor Marker Testing Market: US, Europe, Japan" report to their offering. Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five yearsExamines trends in the U.S., Europe and JapanReviews current and emerging tumor markersAnalyzes applications of emerging diagnostic technologiesForecasts sales of major tumor markers by country and market segmentProfiles leading market players and potential entrants Companies Mentioned: - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Enzo Biochem - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Thermo Fisher/Life Technologies - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/kj...strategies
MYGN: 34.32 (+0.82), DHR: 86.65 (+0.91), SQNM: 2.95 (+0.11), ENZ: 3.00 (+0.04), DGX: 71.58 (+0.74), CPHD: 58.15 (+0.75), HOLX: 38.71 (+0.75)
Guided Therapeutics strikes out again with LuViva PMA
Seeking Alpha - at Seeking Alpha - Tue May 19, 5:10PM CDT
FDA Completes Review of Guided Therapeutics' LuViva(R) Advanced Cervical Scan PMA Application
Business Wire - Tue May 19, 3:05PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval (PMA) application for the LuViva(R) Advanced Cervical Scan. In its most recent communication, FDA advised the Company that its PMA amendment, filed in July 2014, was not approvable in its current form. While the agency advised the Company that more patient data would likely be necessary to amend the current application, the agency also stated its willingness to consider alternative approaches to move the product to approvable form.
Guided Therapeutics' (GTHP) CEO Gene Cartwright on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 1:54PM CDT
Guided Therapeutics Reports First Quarter 2015 Results
Business Wire - Wed May 13, 3:05PM CDT
--FDA response on amended LuViva PMA application expected by end of May
County Government of Nairobi, Kenya Purchases Initial LuViva(R) Advanced Cervical Scan for Cervical Cancer Screening Program
Business Wire - Wed May 06, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that Stem World Enterprises, its distributor for East Africa, has been awarded a contract with the Nairobi County Health Services Sector to supply the first LuViva(R) Advanced Cervical Scan for the agency's cervical cancer screening program.
Guided Therapeutics to Report First Quarter 2015 Results and Hold Conference Call; Provide Update on LuViva FDA Timing
Business Wire - Wed Apr 29, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a point-of-care and painless testing platform that uses biophotonics for the early detection of disease that leads to cervical cancer, today announced that it is scheduled to report financial results for its first quarter ended March 31, 2015 and provide an update on business activity on Wednesday, May 13, 2015, after the market closes.
Penny Stocks Alerts for NEW GENERATION CONSU, Vapor Group, Guided Therapeutics, Jammin Java, MassRoots, and Max Sound
PR Newswire - Tue Apr 21, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: NEW GENERATION CONSU (OTCMKTS:NGCG), Vapor Group (OTCMKTS:VPOR), Guided Therapeutics (OTCBB:GTHP), Jammin Java (OTCMKTS:JAMN), MassRoots (OTCMKTS:MSRT), and Max Sound (OTCBB:MAXD).
Canadian Pilot Programs Initiated with LuViva(R) Advanced Cervical Scan for Provincial-level Cancer Care Support
Business Wire - Tue Apr 21, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today an initiative for procuring provincial-level support for its LuViva Advanced Cervical Scan. The initiative is based on discussions with women's healthcare experts across Canada, whose interest has increased after reviewing positive results from two previous evaluations completed in Halifax, Nova Scotia, with Dr. James Bentley and most recently in London, Ontario, with Drs. Robert DiCecco and Monique Bertrand.
Week In Review: Menarini And Lummy Announce Novel Drug In-Licensings For China
ChinaBio Today - at Seeking Alpha - Sat Apr 18, 12:07PM CDT
Deals and Financings Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an...
BSX: 17.60 (+0.15), ARGS: 6.45 (+0.69), PKI: 51.53 (+0.51)
Guided Therapeutics Completes Interim Financing; Initiating Distribution of LuViva(R) Advanced Cervical Scan in China
Business Wire - Wed Apr 15, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has completed the sale of 4.0 million shares of our common stock and warrants to purchase an additional 2.0 million shares, for an aggregate purchase price of $720,000 in a private placement to accredited investors.
Guided Therapeutics Ships First Commercial LuViva(R) Advanced Cervical Scans to Indonesia
Business Wire - Wed Apr 08, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has shipped two LuViva(R) Advanced Cervical Scans to Indonesia to begin cervical cancer screening evaluations in the world's fourth most populous country.
